Prevention and control of influenza: Recommendations of the Advisory Committee on Immunization Practices (ACIP)

Morbidity and Mortality Weekly Report

Volumn 48, Issue 4, 1999, Pages 1-28

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

AMANTADINE; ANTIVIRUS AGENT; INFLUENZA VACCINE; RIMANTADINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; COST OF ILLNESS; CROSS INFECTION; EPIDEMIC; FEMALE; HUMAN; INFANT; INFLUENZA; INFLUENZA VIRUS A; INFLUENZA VIRUS B; MALE; MIDDLE AGED; NEWBORN; PRACTICE GUIDELINE; PRESCHOOL CHILD; RISK FACTOR; STANDARD; VACCINATION;

ADOLESCENT; ADULT; AGED; AMANTADINE; ANTIVIRAL AGENTS; CHILD; CHILD, PRESCHOOL; COST OF ILLNESS; CROSS INFECTION; DISEASE OUTBREAKS; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; INFLUENZA A VIRUS; INFLUENZA B VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; RIMANTADINE; RISK FACTORS; VACCINATION;

EID: 0033616957     PISSN: 01492195     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (147)

1. Simonsen L, Schonberger LB, Stroup DF, Arden NH, Cox NJ. The impact of influenza on mortality in the USA. In: Brown LE, Hampson AW, Webster RG, eds. Options for the control of influenza III. Amsterdam: Elsevier Science BV, 1996:26-33.
2. Lui K-J, Kendal AP. Impact of influenza epidemics on mortality in the United States from October 1972 to May 1985. Am J Public Health 1987;77:712-6.
3. Monto AS, Kioumehr F. The Tecumseh study of respiratory illness. IX. Occurrence of influenza in the community, 1966-1971. Am J Epidemiol 1975;102:553-63.
4. Glezen WP, Couch RB. Interpandemic influenza in the Houston area, 1974-76. N Engl J Med 1978;298:587-92.
5. Barker WH. Excess pneumonia and influenza associated hospitalisation during influenza epidemics in the United States, 1970-78. Am J Public Health 1986,76:761-5.
6. Barker WH, Mullooly JP. Impact of epidemic type A influenza in a defined adult population. Am J Epidemiol 1980;112:798-811.
7. Glezen WP. Serious morbidity and mortality associated with influenza epidemics [Review]. Epidemiol Rev 1982;4:25-44.
8. CDC. Influenza and pneumococcal vaccination coverage levels among persons aged ≥65 years. MMWR 1995;44:506-7,513-5.
9. CDC. Influenza and pneumococcal vaccination levels among adults aged ≥65 years. MMWR 1998;47:797-802.
10. Public Health Service. Healthy people 2000: national health promotion and disease prevention objectives - full report, with commentary. Washington, DC: US Department of Health and Human Services, Public Health Service, 1991; DHHS publication no. (PHS)91-50212.
11. CDC. Implementation of the Medicare influenza vaccination benefit-United States, 1993. MMWR 1994; 43:771-3.
12. Nichol KL, Lind A, Margolis KL, et al. The effectiveness of vaccination against influenza in healthy, working adults. N Engl J Med 1995;333:889-93.
13. Belshe RB, Mendelman PM, Treanor J, et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine in children. N Eng J J Med 1998;338:1405-12.
14. Clements DA, Langdon L, Bland C, Walter E. Influenza A vaccine decreases the incidence of otitis media in 6- to 30-month-old children in day care. Arch Pediatr Adolesc Med 1995; 149:1113-7.
15. Heikkinen T, Ruuskanen O, Waris M, Ziegler T, Arola M, Halonen P. Influenza vaccination in the prevention of acute otitis media in children. Am J Dis Child 1991;145:445-8.
16. Walker FJ, Singleton JA, Greby SM, Strikas RA. Influenza and pneumococcal vaccination of adults aged 18-64 years, United States, 1995 [Abstract]. In: Abstracts of the 33rd National Immunization Conference. Atlanta, GA: CDC, 1999 (in press).
17. Kramarz P, DeStefano F, Gargiullo P, Chen R, Vaccine Safety Datalink Team. Determinants of influenza vaccination in children with asthma in four health maintenance organizations [Abstract]. 1998 Epidemic Intelligence Service Conference. Atlanta, GA: CDC, 1998.
18. Murphy BR, Webster RG. Orthomyxoviruses. In: Fields BN, Knipe DM, Howley PM, et al, eds. Fields virology. Third edition. Philadelphia, PA: Lippincott-Raven Publishers, 1996; 1397-445.
19. Clements ML, Betts RF, Tierney EL, Murphy BR. Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J Clin Microbiol 1986;24:157-60.
20. Couch RB, Kasel JA. Immunity to influenza in man [Review]. Annu Rev Microbiol 1983;37: 529-49.
21. Nicholson KG. Clinical features of influenza. Semin Respir Infect 1992;7:26-37.
22. Noble GR. Epidemiological and clinical aspects of influenza. In: Beare AS, ed. Basic and applied influenza research. Boca Raton, FL: CRC Press, 1982:11-50.
23. Eickhoff TC, Sherman IL, Serfling RE. Observations on excess mortality associated with epidemic influenza. JAMA 1961;176:776-82.
24. Barker WH, Mullooly JP. Pneumonia and influenza deaths during epidemics: implications for prevention. Arch Intern Med 1982;142:85-9.
25. Lui K-J, Kendal AP. Impact of influenza epidemics on mortality in the United States from October 1972 to May 1985. Am J Public Health 1987;77:712-6.
26. Glezen WP, Decker M, Perrotta DM. Survey of underlying conditions of persons hospitalized with acute respiratory disease during influenza epidemics in Houston, 1978-1981. Am Rev Resp Dis 1987;136:550-5.
27. Glezen WP. Influenza surveillance in an urban area. Can J Infect Dis 1993;4:272-4.
28. Simonsen L, Clarke MJ, Williamson GD, Stroup DF, Arden NH, Schonberger LB. The impact of influenza epidemics on mortality: introducing a severity index. Am J Public Health 1997; 87:1944-50.
29. Simonsen L, Clarke MJ, Schonberger LB, Arden NA, Cox NJ, Fukuda K. Pandemic versus epidemic influenza mortality: a pattern of changing age distribution. J Infect Dis 1998;178: 53-60.
30. National Center for Health Statistics. Health, United States, 1998. Hyattsville, MD: National Center for Health Statistics, 1998.
31. Patriarca PA, Weber JA, Parker RA, et al. Risk factors for outbreaks of influenza in nursing homes: a case-control study. Am J Epidemiol 1986:124;114-9.
32. Kilbourne ED. Influenza. New York, NY: Plenum Medical Book Company, 1987.
33. La Montagne JR, Noble GR, Quinnan GV, et al. Summary of clinical trials of inactivated influenza vaccine-1978. Rev Infect Dis 1983:5;723-36.
34. Oxford JS, Schild GC, Potter CW, Jennings R. The specificity of the anti-haemagglutinin antibody response induced in man by inactivated influenza vaccine and by natural infection. J Hygiene 1979:82:51-61.
35. Potter CW, Oxford JS. Determinants of immunity to influenza infection in man. Br Med Bull 1979;35:69-75.
36. Hirota Y, Kaji M, Ide S, et al. Antibody efficacy as a keen index to evaluate influenza vaccine effectiveness. Vaccine 1997;15:962-7.
37. Blumberg EA, Albano C, Pruett T, et al. The immunogenicity of influenza virus vaccine in solid organ transplant recipients. Clin Infect Dis 1996;22:295-302.
38. Dorrell L, Hassan I, Marshall S, Chakraverty P, Ong E. Clinical and serological responses to an inactivated influenza vaccine in adults with HIV infection, diabetes, obstructive airways disease, elderly adults and healthy volunteers, Int J STD AIDS 1997;8:776-9.
39. McElhaney JE, Beattie BL, Devine R, Grynoch R, Toth EL, Bleackly RC. Age-related decline in interleukin 2 production in response to influenza vaccine. J Am Geriatr Soc 1990;38:652-8.
40. Gross PA, Hermogenes AW, Sacks HS, Lau J, Levandowski RA. The efficacy of influenza vaccine in elderly persons: a meta-analysis and review of the literature. Ann Intern Med 1995; 123: 518-27.
41. Mullooly JP, Bennett MD, Hornbrook MC, et al. Influenza vaccination programs for elderly persons: cost-effectiveness in a health maintenance organization. Ann Intern Med 1994; 121:947-52.
42. Palache AM. Influenza vaccine: a reappraisal of their use. Drugs 1997;54:841-56.
43. Nichol KL, Margolis KL, Wuorenma J, Von Sternberg T. The efficacy and cost effectiveness of vaccination against influenza among elderly persons living in the community. N Engl J Med 1994;331:778-84.
44. Patriarca PA, Weber JA, Parker RA, et al. Efficacy of influenza vaccine in nursing homes: reduction in illness and complications during an influenza A (H3N2) epidemic. JAMA 1985; 253:1136-9.
45. Arden NH, Patriarca PA, Kendal AP. Experiences in the use and efficacy of inactivated influenza vaccine in nursing homes. In: Kendal AP, Patriarca PA, eds. Options for the control of influenza. New York, NY: Alan R. Liss Inc., 1986:155-68.
46. Noble GR. Epidemiological and clinical aspects of influenza. In: Beare AS, ed. Basic and applied influenza research. Boca Raton, FL: CRC Press, 1982:41-2.
47. Harris JW. Influenza occurring in pregnant women: a statistical study of thirteen hundred and fifty cases. JAMA 1919;72:978-80.
48. Widelock D, Csizmas L, Klein S. Influenza, pregnancy, and fetal outcome. Public Health Rep 1963;78:1-11.
49. Freeman DW, Barno A. Deaths from Asian influenza associated with pregnancy. Am J Obstet Gynecol 1959;78:1172-5.
50. Shahab SZ, Glezen WP. Influenza virus. In: Gonik B, ed. Viral diseases in pregnancy. New York, NY: Springer-Verlag, 1994:215-23.
51. Schoenbaum SC, Weinstein L. Respiratory infection in pregnancy. Clin Obstet Gynecol 1979; 22:293-300.
52. Kirshon B, Faro S, Zurawin RK, Samo TC, Carpenter RJ. Favorable outcome after treatment with amantadine and ribavirin in a pregnancy complicated by influenza pneumonia: a case report. J Reprod Med 1988;33:399-401.
53. Kort BA, Cefalo RC, Baker W. Fatal influenza A pneumonia in pregnancy. Am J Perinatol 1986; 3:179-82.
54. Neuzil KM, Reed GW, Mitchel EF, Simonsen L, Griffin MR. Impact of influenza on acute cardiopulmonary hospitalizations in pregnant women. Am J Epidemiol 1998;148:1094-102.
55. Heinonen OP, Shapiro S, Monson RR, Hartz SC, Rosenberg L, Slone D. Immunization during pregnancy against poliomyelitis and influenza in relation to childhood malignancy. Int J Epidemiol 1973;2:229-35.
56. Couch RB. Editorial response: influenza, influenza virus vaccine, and human immunodeficiency virus infection. Clin Infect Dis 1999;28:548-51.
57. Neuzil KM, Reed GW, Mitchel EF, Griffin MR. Influenza-associated morbidity and mortality in young and middle-aged women. JAMA 1999;281:901-7.
58. Safrin S, Rush JD, Mills J. Influenza in patients with human immunodeficiency virus infection. Chest 1990;98:33-7.
59. Radwan H, Ellison R. Severe influenza pneumonia in HIV patients during 1997-1998 influenza season. Presented as a poster at Infectious Diseases Society of America 36th Annual Meeting. Alexandria, VA: Infectious Diseases Society of America, 1998.
60. Chadwick EG, Chang G, Decker MD, Yogev R, Dimichele D, Edwards KM. Serologic response to standard inactivated influenza vaccine in human immunodeficiency virus-infected children. Pediatr Infect Dis J 1994;13:206-11.
61. Huang K-L, Ruben FL, Rinaldo CR, Kingsley L, Lyter DW, Ho M. Antibody responses after influenza and pneumococcal immunization in HIV-infected homosexual men. JAMA 1987; 257:2047-50.
62. Staprans SI, Hamilton BL, Follansbee SE, et al. Activation of virus replication after vaccination of HIV-1-infected individuals. J Exp Med 1995;182:1727-37.
63. Kroon FP, van Dissel JT, de Jong JC, van Furth R. Antibody response to influenza, tetanus and pneumococcal vaccines in HIV-seropositive individuals in relation to the number of CD4+ lymnphocytes. AIDS 1994;8:469-76.
64. Miotti PG, Nelson KE, Dallabetta GA, Farzadegan H, Margolick J, Clements ML. The influence of HIV infection on antibody responses to a two-dose regimen of influenza vaccine. JAMA 1989;262:779-83.
65. Ho DD. HIV-1 viraemia and influenza. Lancet 1992;339:1549.
66. O'Brien WA, Grovit-Ferbas K, Namazi A, et al. Human immunodeficiency virus-type 1 replication can be increased in peripheral blood of seropositive patients after influenza vaccination. Blood 1995;86:1082-9.
67. Glesby MJ, Hoover DR, Farzadegan H, Margolick JB, Saah AJ. The effect of influenza vaccination on human immunodeficiency virus type 1 load: a randomized, double-blind, placebo-controlled study. J Infect Dis 1996;174:1332-6.
68. Fowke KR, D'Amico R, Chernoff DN, et al. Immunologic and virologic evaluation after influenza vaccination of HIV-1-infected patients. AIDS 1997;11:1013-21.
69. Fuller JD, Craven DE, Steger KA, Cox N, Heeren TC, Chernoff D. Influenza vaccination of human immunodeficiency virus (HIV)-infected adults: impact on plasma levels of HIV type 1 RNA and determinants of antibody response. Clin Infect Dis 1999;28:541-7.
70. Cate TR, Couch RB, Parker D, Baxter B. Reactogenicity, immunogenicity, and antibody persistence in adults given inactivated influenza virus vaccines - 1978. Rev Infect Dis 1983; 5:737-47.
71. Künzel W, Glathe H, Engelmann H, Van Hoecke C. Kinetics of humoral antibody response to trivalent inactivated split influenza vaccine in subjects previously vaccinated or vaccinated for the first time. Vaccine 1996;14:1108-10.
72. Gross PA, Weksler ME, Quinnan GV Jr, Douglas RG Jr, Gaerlan PF, Denning CR. Immunization of elderly people with two doses of influenza vaccine. J Clin Microbiol 1987;25:1763-5.
73. Iorio AM, Alatri A, Francisci D, et al. Immunogenicity of influenza vaccine (1993-94 winter season) in HIV-seropositive and -seronegative ex-intravenous drug users. Vaccine 1997;15: 97-102.
74. Feery BJ, Cheyne IM, Hampson AW, Atkinson MIE. Antibody response to one and two doses of influenza virus subunit vaccine. Med J Aust 1976;1:186, 188-9.
75. Howells CHL, Evans AD, Vesselinova-Jenkins C. Effect of two doses of influenza vaccine in stimulating antibody in volunteers. Lancet 1973;1:1436-8.
76. CDC. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1994;43(No. RR-1):1-36.
77. Govaert ME, Dinant GJ, Aretz K, Masurel N, Sprenger MJW, Knottnerus JA. Adverse reactions to influenza vaccine in elderly people: randomised double blind placebo controlled trial. BMJ 1993;307:988-90.
78. Margolis KL, Nichol KL, Poland GA, Pluhar RE. Frequency of adverse reactions to influenza vaccine in the elderly: a randomized, placebo-controlled trial. JAMA 1990;264:1139-41.
79. Nichol KL, Margolis KL, Lind A, et al. Side effects associated with influenza vaccination in healthy working adults: a randomized, placebo-controlled trial. Arch Intern Med 1996; 156:1546-50.
80. Scheifele DW, Bjornson G, Johnson J. Evaluation of adverse events after influenza vaccination in hospital personnel. Can Med Assoc J 1990;142:127-30.
81. Barry DW, Mayner RE, Hochstein HD, et al. Comparative trial of influenza vaccine. II. Adverse reactions in children and adults. Am J Epidemiol 1976;104:47-59.
82. Bierman CW, Shapiro GG, Pierson WE, Taylor JW, Foy HM, Fox JP. Safety of influenza vaccination in allergic children. J Infect Dis 1997;136;S652-S655.
83. James JM, Zeiger RS, Lester MR, et al. Safe administration of influenza vaccine to patients with egg allergy. J Pediatr 1998;133:624-8.
84. Murphy KR, Strunk RC. Safe administration of influenza vaccine in asthmatic children hypersensitive to egg proteins. J Pediatr 1985;106:931-3.
85. Aberer W. Vaccination despite thimerosal sensitivity. Contact Dermatitis 1991;24:6-10.
86. Kirkland LR. Ocular sensitivity to thimerosal: A problem with hepatitis B vaccine? South Med J 1990;83:497-9.
87. Schonberger LB, Bregman DJ, Sullivan-Bolyai JZ, et al. Guillain-Barre syndrome following vaccination in the National Influenza Immunization Program, United States, 1976-1977. Am J Epidemiol 1979;110:105-23.
88. Safranek TJ, Lawrence DN, Kurland LT, et al. Reassessment of the association between Guillain-Barre syndrome and receipt of swine influenza vaccine in 1976-1977: results of a two-state study. Expert Neurology Group. Am J Epidemiol 1991;133:940-51.
89. Ropper AH. The Guillain-Barré syndrome. N Engl J Med 1992;326:1130-6.
90. Hurwitz ES, Schonberger LB, Nelson DB, Holman RC. Guillain-Barré syndrome and the 1978-1979 influenza vaccine. N Engl J Med 1981;304:1557-61.
91. Kaplan JE, Katona P, Hurwitz ES, Schonberger LB. Guillain-Barré syndrome in the United States, 1979-1980 and 1980-1981. JAMA 1982;248:698-700.
92. Chen R, Kent J, Rhodes P, Simon P, Schonberger L. Investigation of a possible association between influenza vaccination and Guillain-Barré syndrome in the United States, 1990-1991 [Abstract]. Post Marketing Surveillance 1992;6:5-6.
93. Lasky T, Terracciano GJ, Magder L, et al. The Guillain-Barré syndrome and the 1992-1993 and 1993-1994 influenza vaccines. N Engl J Med 1998;339:1797-802.
94. Flewett TH, Hoult JG. Influenzal encephalopathy and postinfluenzal encephalitis. Lancet 1958; 2:11-5.
95. Horner FA. Neurologic disorders after Asian influenza. N Engl J Med 1958;258:983-5.
96. Jacobs BC, Rothbarth PH, van der Meche FG, et al. The spectrum of antecedent infections in Guillain-Barre syndrome: a case-control study. Neurology 1998;51:1110-5.
97. Guarino M, Casmiro M, D'Alessandro R. Campylobacter jejuni infection and Guillain-Barré syndrome: a case-control study. Neuroepidemiology 1998;17:296-302.
98. Sheikh KA, Nachamkin I, Ho TW, et al. Campylobacter jejuni lipopolysaccharides in Guillain-Barre syndrome: molecular mimicry and host susceptibility. Neurology 1998;51:371-8.
99. Prevots DR, Sutter RW. Assessment of Guillain-Barré syndrome mortality and morbidity in the United States: implications for acute flaccid paralysis surveillance. J Infect Dis 1997;175 (Suppl 1):S151-S155.
100. Barohn RJ, Saperstein DS. Guillain-Barre syndrome and chronic inflammatory demyelinating polyneuropathy [Review]. Semin Neurol 1998;18:49-61.
101. CDC. Prevention of pneumococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 1997;46(No. RR-8):1-24.
102. Grilli G, Fuiano L, Biasio LR, Pregliasco F, et al. Simultaneous influenza and pneumococcal vaccination in elderly individuals. Eur J Epidemiol 1997;13:287-91.
103. Fletcher TJ, Tunnicliffe WS, Hammond K, Roberts K, Ayres JG. Simultaneous immunisation with influenza vaccine and pneumococcal polysaccharide vaccine in patients with chronic respiratory disease. BMJ 1997;314:1663-5.
104. Kendal AP, Maassab HF, Alexandrova GI, Ghendon YZ. Development of cold-adapted recombinant live, attenuated influenza A vaccines in the USA and USSR. Antiviral Res 1981;1:339-65.
105. Maassab HF, DeBorde DC. Development and characterization of cold-adapted viruses for use as live virus vaccines. Vaccine 1985;3:355-69.
106. Murphy BR. Use of live attenuated cold-adapted influenza A reassortant virus vaccines in infants, children, young adults, and elderly adults. Infect Dis Clin Pract 1993;2:174-81.
107. Potter CW. Attenuated influenza virus vaccines. Med Virol 1994;4:279-92.
108. Clements ML, Stephens I. New and improved vaccines against influenza. In: Levine MM, Woodrow GC, Kaper JB, Cobon GS, eds. New Generation Vaccines, 2nd edition. New York, NY: Marcel Dekker, 1997:545-70.
109. Edwards KM, Dupont WD, Westrich MK, Plummer WD Jr, Palmer PS, Wright PF. A randomized controlled trial of cold-adapted and inactivated vaccines for the prevention of influenza A disease. J Infect Dis 1994;169:68-76.
110. Belshe R, Iacuzio D, Mendelman P, Wolff M. Efficacy of trivalent live attenuated intranasal influenza vaccine in children. In: Programs and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society of Microbiology, 1998.
111. Mullooly JP, Barker WH. Impact of type A influenza on children: a retrospective study. Am J Public Health 1982;72:1008-16.
112. Glezen WP, Decker M, Joseph SW, Mercready RG Jr. Acute respiratory disease associated with influenza epidemics in Houston, 1981-1983. J Infect Dis 1987;155:1119-25.
113. Cooney MK, Fox JP, Hall CE. The Seattle Virus Watch. VI. Observations of infections with and illness due to parainfluenza, mumps and respiratory syncytial viruses and Mycoplasma pneumoniae. Am J Epidemiol 1975;101:532-51.
114. Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child 1986;140:543-6.
115. Glezen WP. Morbidity associated with the major respiratory viruses. Pediatr Ann 1990;19: 535-42.
116. Couch RB, Kasel JA, Glezen WP, et al. Influenza: its control in persons and populations. J Infect Dis 1986;153:431-40.
117. Keyser LA, Karl M, Nafziger AN, Bertino JS Jr. Comparison of adverse events (AEs) of amantadine (AM) and rimantadine (RM) used as sequential prophylaxis of influenza A (FLU) in elderly nursing home residents. In: Programs and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society of Microbiology, 1998.
118. Dolin R, Reichman RC, Madore HP, Maynard R, Linton PN, Webber-Jones J. A controlled trial of amantadine and rimantadine in the prophylaxis of influenza A infection. N Engl J Med 1982;307:580-4.
119. Gross PA, Russo C, Dran S, Cataruozolo P, Munk G, Lancey SC. Time to earliest peak serum antibody response to influenza vaccine in the elderly. Clin Diagn Lab Immunol 1997;4:491-2.
120. Brokstad KA, Cox RJ, Olofsson J, Jonsson R, Haaheim LR. Parental influenza vaccination induces a rapid systemic and local immune response. J Infect Dis 1995;171:198-203.
121. Tominack RL, Hayden FG. Rimantadine hydrochloride and amantadine hydrochloride use in influenza A virus infections. Infect Dis Clin North Am 1987;1:459-78.
122. Soung L-S, Ing TS, Daugirdas JT, et al. Amantadine hydrochloride pharmacokinetics in hemodialysis patients. Ann Intern Med 1980;93(Part 1):46-9.
123. Capparelli EV, Stevens RC, Chow MSS, Izard M, Wills RJ. Rimantadine pharmacokinetics in healthy subjects and patients with end-stage renal failure. Clin Pharmacol Ther 1988;43:536-41.
124. Schnack H, Wewalka F, Guttmann G. Liver function during amantadine hydrochloride medication in compensated liver disease. Internationale Zeitschrift für Klinische Pharmakologie, Therapie, und Toxikologie 1969;2:185-7.
125. Atkinson WL, Arden NH, Patriarca PA, Leslie N, Lui K-J, Gohd R. Amantadine prophylaxis during an institutional outbreak of type A(H1N1) influenza. Arch Intern Med 1986;146:1751-6.
126. Soo W. Adverse effects of rimantadine: summary from clinical trials. J Respir Dis 1989:10: S26-S31.
127. Bleidner WE, Harmon JB, Hewes WE, Lynes TE, Hermann EC. Absorption, distribution and excretion of amantadine hydrochloride. J Pharmacol Exp Ther 1965;150:484-90.
128. Douglas RG Jr. Drug therapy: prophylaxis and treatment of influenza. N Engl J Med 1990;322: 443-50.
129. Aoki FY, Sitar DS. Clinical pharmacokinetics of amantadine hydrochloride. Clin Pharmacokinet 1988;14:35-51.
130. Aoki FY, Sitar DS. Amantadine kinetics in healthy elderly men: implications for influenza prevention. Clin Pharmacol Ther 1985;37:137-44.
131. Guay DRP. Amantadine and rimantadine prophylaxis of influenza A in nursing homes: a tolerability perspective. Drugs Aging 1994;5:8-19.
132. Wintermeyer SM, Nahata MC. Rimantadine: a clinical perspective. Ann Pharmacother 1995; 29:299-310.
133. Wills RJ, Belshe R, Tomlinsin D, et al. Pharmacokinetics of rimantadine hydrochloride in patients with chronic liver disease. Clin Pharmacol Ther 1987;42:449-54.
134. Forest Pharmaceuticals. Flumadine® tablets. Flumadine® syrup (rimantadine hydrochloride) [Package insert]. St. Louis, MO: Forest Pharmaceuticals, 1993.
135. Wills RJ. Update on rimantadine's clinical pharmacokinetics. J Respir Dis 1989;10(suppl): S20-S25.
136. Belshe RB, Smith MH, Hall CB, Betts R, Hay AJ. Genetic basis of resistance to rimatadine emerging during treatment of influenza virus infection. J Virol 1988;62:1508-12.
137. Hall CB, Dolin R, Gala CL, et al. Children with influenza A infection: treatment with rimantadine. Pediatrics 1987;80:275-82.
138. Hayden FG, Sperber SJ, Belshe RB, Clover RD, Hay AJ, Pyke S. Recovery of drug-resistant influenza A virus during therapeutic use of rimantadine. Antimicrob Agents Chemother 1991; 35:1741-7.
139. Houck P, Hemphill M, LaCroix S, Hirsh D, Cox N. Amantadine-resistant influenza A in nursing homes. Identification of a resistant virus prior to drug use. Arch Intern Med 1995;155:533-7.
140. Hayden FG, Belshe RB, Clover RD, Hay AJ, Oakes MG, Soo W. Emergence and apparent transmission of rimatadine-resistant influenza A virus in families. N Engl J Med 1989;321:1696-702.
141. Mast EE, Harmon MW, Gravenstein S, et al. Emergence and possible transmission of amantadine-resistant viruses during nursing home outbreaks of influenza A (H3N2). Am J Epidemiol 1991;134:988-97.
142. Hayden FG, Hay AJ. Emergence and transmission of influenza A viruses resistant to amantadine and rimantadine. Curr Top Microbiol Immunol 1992;176:119-30.
143. Degelau J, Somani SK, Cooper SL, Guay DRP, Crossley KB. Amantadine-resistant influenza A in a nursing facility. Arch Intern Med 1992;152:390-2.
144. Calfee DR, Hayden FG. New approaches to influenza chemotherapy: neuraminidase inhibitors [Review]. Drugs 1998;56:537-53.
145. Hayden FG, Treanor JJ, Betts RF, Lobo M, Esinhart JD, Hussey EK. Safety and efficacy of the neuraminidase inhibitor GG167 in experimental human influenza. JAMA 1996;275:295-9.
146. Hayden FG, Osterhaus ADME, Treanor JJ, et al., for the GG167 Influenza Study Group. Efficacy and safety of the neuraminidase inhibitor zanamivir in the treatment of influenzavirus infections. N Engl J Med 1997;337:874-80.
147. Anonymous. Randomised trial of efficacy and safety of inhaled zanamivir in treatment of influenza A and B virus infections. The MIST (Management of Influenza in the Southern Hemisphere Trialists) Study Group. Lancet 1998;352:1877-81.